Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai Succeeds Parkinson’s Disease Med Equfina from Meiji Pharma on Sept. 23
September 8, 2020
- Keytruda Returns to Top Spot After 2 Months in August Sales Ranking: Encise
September 7, 2020
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat to Be Filed in US in Early 2021
September 7, 2020
- AstraZeneca Launches Japan PI/II Study of COVID-19 Vaccine; Submission Could Be Possible Based on Results
September 7, 2020
- Blackstone Setting Sights on IPO of Takeda Consumer Healthcare Within 5-10 Years
September 4, 2020
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Approved for Chronic Idiopathic Thrombocytopenic Purpura
September 4, 2020
- US Launch of Takeda’s Entyvio SC to Be Pushed Back to 2022
September 4, 2020
- Flawed Testing at Kyowa CritiCare Costs 2 More Product Recalls
September 4, 2020
- Aspen Japan Completes Takeover of Marketing Authorization, Distribution Rights for Lexotan
September 3, 2020
- Mitsubishi Tanabe to Develop Mobile App for Depression Treatment
September 3, 2020
- LTL Pharma to License Dellegra AG to Nichi-Iko, Eyeing December Rollout
September 3, 2020
- Mitsubishi Tanabe’s HIF-PH Inhibitor Hit by Shortage Days after Launch on Better-than-Expected Demand
September 2, 2020
- Janssen Launches Japan PI Study for Coronavirus Vaccine
September 2, 2020
- Gilead Revises Veklury Label Warning of Coadministration with Hydroxychloroquine or Chloroquine
September 2, 2020
- Taisho, Takeda to Wind Up Japan Distribution Deal for Biofermin’s Prescription Drugs
September 2, 2020
- Fujifilm Files Radiopharmaceutical Drug F-1515 in Japan
September 1, 2020
- Japan Sees Showdown of 3 HIF-PH Inhibitors as 2 New Drugs Enter Market
September 1, 2020
- Sanofi’s Sarclisa Hits Japan Market, Zeria Launches Ferinject
September 1, 2020
- Edoxaban Hits PIII Goal in Very Elderly Patients: Daiichi Sankyo
September 1, 2020
- Sales Rep Promotions Up in July, but Online Channels Down: Intage
August 31, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…